The latest price target for MediciNova (NASDAQ:MNOV) was reported by D. Boral Capital on December 6, 2024. The analyst firm set a price target for $9.00 expecting MNOV to rise to within 12 months (a possible 314.75% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for MediciNova (NASDAQ:MNOV) was provided by D. Boral Capital, and MediciNova maintained their buy rating.

There is no last upgrade for MediciNova

There is no last downgrade for MediciNova.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MediciNova, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MediciNova was filed on December 6, 2024 so you should expect the next rating to be made available sometime around December 6, 2025.

While ratings are subjective and will change, the latest MediciNova (MNOV) rating was a maintained with a price target of $9.00 to $9.00. The current price MediciNova (MNOV) is trading at is $2.17, which is out of the analyst’s predicted range.